Form 4: Verona Pharma General Counsel Reports Significant Share Activity Following RSU Vesting

Verona Pharma plc's General Counsel, Andrew Fisher, reported the acquisition of ordinary shares and restricted share units, alongside a tax-related disposition of shares, following the vesting of performance-based awards.

Summary

• Andrew Fisher, General Counsel of Verona Pharma plc, reported transactions involving the company's securities.
• On July 7, 2025, Fisher acquired 86,064 Ordinary Shares at a price of $0, resulting from the exercise or vesting of derivative securities.
• Following this acquisition, Fisher's beneficial ownership of Ordinary Shares increased to 446,063.
• On July 8, 2025, Fisher disposed of 39,464 Ordinary Shares at a price of $11.4413 per share to satisfy tax withholding obligations related to the vesting of previously reported Restricted Share Units.
• After the tax-related disposition, Fisher's beneficial ownership of Ordinary Shares was 406,599.
• On July 7, 2025, Fisher was awarded 253,120 performance-based Restricted Share Units (RSUs) at a price of $0.
• On the same date, 86,064 RSUs were disposed of, likely due to their conversion into Ordinary Shares upon vesting.
• Following these RSU transactions, Fisher holds 167,056 Restricted Share Units.
• The Ordinary Shares are represented by American Depositary Shares (ADSs), where each ADS represents eight Ordinary Shares.
• The price of $11.4413 for the disposed shares was derived from the closing price of Verona Pharma's ADSs on the Nasdaq Stock Market LLC on July 3, 2025, divided by eight.
• The RSUs were earned because the Board of Directors determined that certain performance metrics related to Q2 2025 had been achieved.
• 34% of the total RSUs vested on the Determination Date (July 7, 2025), with the remaining shares vesting in equal quarterly installments over a two-year period on November 1, February 1, May 1, and August 1, contingent on Fisher's continued service.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the successful achievement of performance metrics leading to RSU vesting, indicating good operational performance for Q2 2025. The share disposition is for tax purposes and is a neutral event.

Positives

• The vesting of performance-based Restricted Share Units indicates that Verona Pharma achieved its Q2 2025 performance metrics, reflecting positive operational execution.
• The acquisition of 86,064 Ordinary Shares at a $0 price point suggests the successful conversion of equity awards, increasing the executive's direct stake in the company.

Negatives

• A disposition of 39,464 Ordinary Shares occurred to cover tax withholding obligations, which is a common but non-discretionary sale by an insider.

Future Outlook

The remaining Restricted Share Units (RSUs) will vest in equal quarterly installments over a two-year period on November 1, February 1, May 1, and August 1, contingent on the reporting person's continued service to the Issuer.

Management Comments

• The Board of Directors determined that certain performance metrics related to Q2 2025 had been achieved, leading to the earning and initial vesting of performance-based Restricted Share Units.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, specifically related to executive compensation and equity vesting. It does not provide broader industry context or trends, but reflects standard practices for public company executive incentive plans.

Stakeholder Impact

• Shareholders gain transparency into executive compensation and changes in insider ownership, which can signal management's alignment with shareholder interests.
• Employees, particularly those with similar equity compensation plans, may see this as an indicator of the company's performance and the potential for their own awards to vest.

Next Steps

• Continued quarterly vesting of the remaining Restricted Share Units on November 1, February 1, May 1, and August 1 over a two-year period, subject to continued service.

Key Dates

Keywords

Verona Pharma, VRNA, Form 4, Insider Transaction, Restricted Share Units, RSU Vesting, Executive Compensation, Share Ownership, Andrew Fisher, Performance Metrics